Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, shares the findings from a single center Phase II trial of CD19-targeted CAR-T cell therapy in patients with chronic lymphocytic leukemia (CLL) with disease transformation. Those enrolled in the trial included patients with Richter’s transformation, accelerated CLL and prolymphocytic transformations. The therapy was demonstrated as safe and produced a high complete remission rate. CAR-T therapy is a promising option for these patients, but longer-term follow-up is needed to understand the durability of remission. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.